According to a 2025 analysis of Global Burden of Disease data published in the Journal of the American College of Cardiology, approximately 59 million people worldwide are living with AF. Catheter ablation is an established treatment recommended as a first-line rhythm control therapy for selected patients under the 2023 ACC/AHA/ACCP/HRS clinical guidelines, yet approximately 30% to 40% of patients experience recurrent AF following an initial ablation procedure despite advances in ablation technology, including pulsed field ablation. StimCardio’s lead investigational product, Rhyvive, is a wrist-worn therapeutic wearable designed to deliver personalized, non-invasive median nerve stimulation through a closed-loop system integrating physiological sensing and neuromodulation. Developed as an adjunct to catheter ablation, Rhyvive is designed to extend treatment beyond the procedure and into the patient’s home by modulating autonomic nervous system pathways with the goal of reducing recurrent atrial arrhythmias.
